Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOTH Hoth Therapeutics	$1.28 -0.8%	$1.29	$0.60 ▼ $3.80	$16.97M	0.66	312,500 shs	187,458 shs
LSB LakeShore Biopharma	$0.78 -1.3%	$0.97	$0.59 ▼ $8.60	$16.20M	0.56	96,809 shs	27,444 shs
SYBX Synlogic	$1.48 +2.1%	$1.36	$0.90 ▼ $1.96	$17.31M	0.52	80,472 shs	15,101 shs
XBIO Xenetic Biosciences	$2.86 -2.1%	$3.36	$2.20 ▼ $5.27	$4.41M	2.31	44,915 shs	2,879 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOTH Hoth Therapeutics	0.00%	+7.56%	-4.48%	+48.80%	+116.95%
LSB LakeShore Biopharma	0.00%	+11.43%	-29.73%	-31.58%	-82.27%
SYBX Synlogic	0.00%	+5.71%	-12.43%	+37.04%	+4.96%
XBIO Xenetic Biosciences	0.00%	+3.25%	-22.49%	-1.72%	-13.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOTH Hoth Therapeutics	3.1025 of 5 stars	3.6	5.0	3.0	0.0	0.6
LSB LakeShore Biopharma	1.5056 of 5 stars	0.0	5.0	3.0	0.8	0.6
SYBX Synlogic	0.9662 of 5 stars	0.0	3.0	2.5	1.7	0.6
XBIO Xenetic Biosciences	1.1506 of 5 stars	0.0	3.0	2.6	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOTH Hoth Therapeutics	3.25	Buy	$4.00	212.50% Upside
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A
SYBX Synlogic	0.00	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIO, SYBX, LSB, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
LSB LakeShore Biopharma	$614.96M	0.03	N/A	N/A	$3.35 per share	0.23
SYBX Synlogic	$10K	1,731.60	N/A	N/A	$1.08 per share	1.37
XBIO Xenetic Biosciences	$2.50M	1.76	N/A	N/A	$2.88 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	N/A
LSB LakeShore Biopharma	-$13.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	-8.09%	-5.50%	N/A
XBIO Xenetic Biosciences	-$3.96M	-$2.00	N/A	N/A	N/A	-126.08%	-54.56%	-47.28%	N/A

Latest XBIO, SYBX, LSB, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/12/2025	Q2 2025	XBIO Xenetic Biosciences	-$0.64	-$0.45	+$0.19	-$0.45	$0.48 million	$0.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOTH Hoth Therapeutics	N/A	27.54	15.08
LSB LakeShore Biopharma	0.05	1.02	0.75
SYBX Synlogic	N/A	3.63	3.63
XBIO Xenetic Biosciences	N/A	5.93	8.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOTH Hoth Therapeutics	7.08%
LSB LakeShore Biopharma	52.64%
SYBX Synlogic	63.40%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
HOTH Hoth Therapeutics	6.92%
LSB LakeShore Biopharma	N/A
SYBX Synlogic	3.02%
XBIO Xenetic Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
LSB LakeShore Biopharma	773	20.77 million	N/A	N/A
SYBX Synlogic	80	11.70 million	11.35 million	Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.32 million	Not Optionable

XBIO, SYBX, LSB, and HOTH Headlines

Recent News About These Companies

HC Wainwright Issues Positive Estimate for XBIO Earnings

August 17 at 2:04 AM | americanbankingnews.com

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

August 13, 2025 | accessnewswire.comA

Xenetic Biosciences Reports Improved Financial Performance

August 13, 2025 | msn.com

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2025 | zacks.com

Xenetic Biosciences (XBIO) to Release Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

July 30, 2025 | accessnewswire.comA

Xenetic Biosciences expands R&D collaboration with The Scripps Research Institute to advance DNase platform

July 26, 2025 | pharmabiz.comP

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

July 23, 2025 | accessnewswire.comA

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the ...

July 8, 2025 | finanznachrichten.de

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

July 8, 2025 | accessnewswire.comA

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | accessnewswire.comA

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

April 9, 2025 | accessnewswire.comA

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

April 9, 2025 | accessnewswire.comA

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

March 26, 2025 | accessnewswire.comA

Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 20, 2025 | finance.yahoo.com

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

March 19, 2025 | accessnewswire.comA

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

March 13, 2025 | accessnewswire.comA

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

February 27, 2025 | accessnewswire.comA

Xenetic Biosciences extends research agreement with University of Virginia for the advancement of its DNase-based oncology platform

December 18, 2024 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO, SYBX, LSB, and HOTH Company Descriptions

Hoth Therapeutics NASDAQ:HOTH

$1.28 -0.01 (-0.78%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.04 (+3.13%)

As of 08/15/2025 07:39 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

LakeShore Biopharma NASDAQ:LSB

$0.78 -0.01 (-1.27%)

As of 08/15/2025 03:59 PM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Synlogic NASDAQ:SYBX

$1.48 +0.03 (+2.07%)

As of 08/15/2025 04:00 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Xenetic Biosciences NASDAQ:XBIO

$2.86 -0.06 (-2.05%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$3.00 +0.14 (+4.72%)

As of 08/15/2025 07:56 PM Eastern

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time